A feasibility study of outpatient chemotherapy with S-1 + cisplatin in patients with advanced gastric cancer

Okazaki, Satoshi; Nakajima, Takako Eguchi; Hashimoto, Jun; Yamamoto, Seiichiro; Takahari, Daisuke; Kato, Ken; Hamaguchi, Tetsuya; Yamada, Yasuhide; Shimada, Yasuhiro; Takagi, Kenji

doi:10.1007/s10120-012-0139-4

Cited by 6 publications

(4 citation statements)

References 14 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients were infused 1000 ml of normal saline before premedication and 1000 ml of normal saline after CDDP administration on day 8. Patients ingest orally 1500 ml of water on day 9 and 10 [8]. Satake et al who is the author in the present study reported that patients were infused 1000 ml of 0.45% NaCl with Mg 2.5 mEq as prehydration and 500 ml of 0.45% NaCl with Mg 2.5 mEq as posthydration with 1000 ml of oral hydration.…”

Section: Discussionmentioning

confidence: 50%

Short Hydration in Chemotherapy with Cisplatin plus S-1 for Advanced or Recurrent Gastric Cancer: A Retrospective Study

Tsuji

Negoro

Okita

et al. 2015

JCT

View full text Add to dashboard Cite

Background: Despite there are a few reports that assessed the S-1 + CDDP regimen with short hydration regimen for unresectable or metastatic gastric cancer, there is no consensus on the best regimen for short hydration. The aim of study was to evaluate the safety and the efficacy of S-1 plus cisplatin doublet chemotherapy with short hydration. Methods: S-1 was administered orally (p.o.) twice daily for the first 3 weeks of a 5-week cycle. Dose of S-1 administered was calculated according to the body surface area. CDDP was given as an intravenous (i.v.) infusion of 60 mg/m 2 on day 8 of each cycle. Patients received the total of 1900 ml infusion containing 1000 ml of acetate Ringer's solution as pre-and post-hydraion. 300 ml of 20% mannitol was administered as a diuretic. Results: 35 patients with unresectable or recurrent gastric cancer were enrolled. The reasons for termination of S-1 + CDDP were as follows: 21 (63.6%) by progressive disease; 12 (31.4%) by toxicity. Even though 12 of 35 patients (34.2%) were discontinued S-1 + CDDP chemotherapy, only one patient was discontinued by Grade 2 of increased creatinine. TTF (time to progression) was 174 days (3 -586 days), and the median of the total number of treatment cycles of S-1 + CDDP was 3.31. Median overall survival, as secondary endpoint, was 518 days. Conclusions: Our study suggested that the short hydration regimen is as safe and efficient as the continuous hydration regimen.

show abstract

Section: Discussionmentioning

confidence: 50%

Short Hydration in Chemotherapy with Cisplatin plus S-1 for Advanced or Recurrent Gastric Cancer: A Retrospective Study

Tsuji

Negoro

Okita

et al. 2015

JCT

View full text Add to dashboard Cite

show abstract

“…However, although dehydration is a risk factor for cisplatin-induced AKI, no seasonal variation was observed for AKI cases with cisplatin in JADER ( Supplementary Figure 1 ). In Japan, almost all chemotherapy with standard-dose cisplatin is administered on an inpatient basis with intravenous hydration (Okazaki et al, 2013), while VACV is typically prescribed to outpatients without hydration, and this may have affected the differences of seasonal distribution observed between VACV and cisplatin. Taken together, these findings indicate the importance of increased clinical awareness of VACV-related AKI in the summer months.…”

Section: Discussionmentioning

confidence: 99%

Risk Evaluation for Acute Kidney Injury Induced by the Concomitant Use of Valacyclovir, Analgesics, and Renin–Angiotensin System Inhibitors: The Detection of Signals of Drug–Drug Interactions

et al. 2019

View full text Add to dashboard Cite

Background: Drug-related acute kidney disease is a common side effect of valacyclovir (VACV) treatment. Although analgesics are frequently administered concomitantly with VACV to treat the pain of herpes zoster, the differences between nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen in relation to VACV-related acute kidney injury (AKI) are unclear. The risk for AKI with concomitant use of VACV and renin–angiotensin system (RAS) inhibitors that can cause AKI via a similar mechanism to NSAIDs is also unknown. We therefore evaluated the association between concomitant use of these drugs and VACV-related AKI, which was characterized according to the Japanese Adverse Drug Event Report (JADER) database. Methods: We analyzed data from the JADER database, which is a spontaneous reporting system. The reporting odds ratio was used to evaluate the signals of AKI. Results: A high proportion of VACV-related AKI cases occurred in summer. There was an increase in AKI signal in cases with concomitant use of VACV and NSAIDs, while no increase was detected in cases with concomitant use of VACV and acetaminophen. AKI events in cases with concomitant use of VACV and NSAIDs were more frequent in older and female patients and those with hypertension. Additionally, a signal increase for VACV-related AKI was observed with concomitant use of RAS inhibitors, with or without NSAIDs. Conclusions: We identified a seasonal variation in VACV-related AKI. Additionally, our findings indicate that acetaminophen might represent a safer analgesic than NSAIDs with respect to VACV-related AKI. We also identified candidate risk factors for AKI with concomitant use of NSAIDs, such as older age, female sex, and hypertension. Although further studies are warranted, our findings highlight the need to consider concomitant drug use and seasonal factors that lead to urinary output loss so that VACV-related AKI can be avoided.

show abstract

“…Regimens with cisplatin at more than 50 mg/m 2 have usually been administered as inpatient chemotherapy because these are highly emetic and require intensive hydration (24). However, cisplatin is known to be commonly administered as outpatient chemotherapy in other countries.…”

Section: Management Of Chemotherapy In Diverse Patientsmentioning

confidence: 99%

Present status and perspective of chemotherapy for patients with unresectable advanced or metastatic gastric cancer in Japan

Yamada

2020

GHM

Self Cite

View full text Add to dashboard Cite

Patients with unresectable advanced or recurrent gastric cancer have a poor prognosis with overall survival times increasing by only a few months after anti-cancer drug therapy in the last four decades. The survival times from previous clinical trials for untreated metastatic gastric cancer in Japan are generally better than those reported from trials in European and North or South American countries. Therefore, the proportion of Japanese patients enrolled in recent global trials of novel anti-cancer drugs should be increased in order to identify drugs that specifically prolong the survival of such patients. S-1 plus oxaliplatin (SOX) therapy is the most commonly used standard first-line treatment for advanced gastric cancer in Japan. SOX induces mild nausea and vomiting, even in elderly patients, that can be treated by maintaining oral intake with adequate anti-emetic treatment usually given in an outpatient clinic. Neutropenia, nausea, and vomiting in SOX therapy were more frequently observed in female patients compared with males. Intensive toxic chemotherapy such as triplet therapy never prolonged overall survival or maintained a favorable quality of life. The current strategies used against metastatic gastric cancer need to be modified in regard to innovative treatments with current drugs, keeping in mind each categorized treatment population. In a real world of a diverse society even if the same treatment is performed, the outcome of the individual patient is different. It is important for each society to implement established treatment, knowing that the evidence from global trials aimed at drug approval does not necessarily show external validity.

show abstract

A feasibility study of outpatient chemotherapy with S-1 + cisplatin in patients with advanced gastric cancer

Cited by 6 publications

References 14 publications

Short Hydration in Chemotherapy with Cisplatin plus S-1 for Advanced or Recurrent Gastric Cancer: A Retrospective Study

Short Hydration in Chemotherapy with Cisplatin plus S-1 for Advanced or Recurrent Gastric Cancer: A Retrospective Study

Risk Evaluation for Acute Kidney Injury Induced by the Concomitant Use of Valacyclovir, Analgesics, and Renin–Angiotensin System Inhibitors: The Detection of Signals of Drug–Drug Interactions

Present status and perspective of chemotherapy for patients with unresectable advanced or metastatic gastric cancer in Japan

Contact Info

Product

Resources

About